Gentris Expands Headquarters and Biorepository
News Sep 14, 2012
Gentris Corporation announces the completion of a significant expansion to their Morrisville, N.C. facility. The first phase of the expansion included additional office space and a large, multipurpose conference room, which will accommodate scientific training and education programs. The second phase of construction tripled the available capacity of the clinical sample biorepository in order to meet future demand.
Gentris continues to invest in capabilities and capacity to address the growing personalized medicine market. As more pharmaceutical companies pursue biomarker-driven therapeutic strategies, there is a growing need to collect and store patient samples for analysis. The expanded biorepository will ensure sufficient capacity to accommodate the sample storage and management needs of pharmaceutical clients that are implementing pharmacogenomics in clinical trials. In addition to biorepository space, Gentris has added a large conference room to host scientific training and education programs that will focus on providing up-to-date information on best practices for integrating pharmacogenomics into drug development.
“As demand for clinical sample storage grows, we needed a larger, dedicated facility for sample management and biosrepository functions,” said Eric Hall, Gentris VP of Clinical Operations and Biorepository. “Pharmaceutical companies are increasingly recognizing the value of banking clinical trial samples for immediate or future testing. By tripling the size of our biorepository space, we have increased our flexibility to manage and store a large number of diverse sample types and serve our rapidly expanding client base.”
“We anticipate an increased need for biorepository and pharmacogenomics testing services as pharmaceutical companies invest in personalized medicine,” said Scott Clark, Gentris Chief Scientific Officer. “The recent expansion will enable us to continue providing high quality solutions to our clients as well as to host training and education programs focused on maximizing the benefits of integrating pharmacogenomics and biobanking into clinical trials.”
New Biomarkers Predict Outcome of Cancer ImmunotherapyNews
Researchers at the University of Zurich have identified biomarkers in the blood that make it possible to predict whether cancer patients will respond positively to immunotherapy. Patients for whom therapy does not work can thus be treated using different methods at an earlier stage.READ MORE
Cellular Judge Rules on Fate of mRNAs under Sugar StressNews
A newly discovered protein, Puf5P, has been shown to arbitrate on which mRNAs are stored and which are destroyed.READ MORE
Peli BioThermal Hires Dominic Hyde as New VP of Crēdo™ on DemandNews
Radical expansion of global rental program includes adding staff, locations and doubling their container inventory.READ MORE